Available in English, French and Spanish
The WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) was launched in 2015 to foster AMR surveillance and inform strategies to contain AMR. The system started with surveillance of AMR in bacteria causing common human infections and has expanded its scope to include surveillance... of antimicrobial consumption (AMC), invasive fungal infections, and a One Health surveillance model relevant to human health. To meet future challenges, it is in continuous evolution to enhance the quality and representativeness of data to inform the AMR burden accurately. As of the end of 2022, 127 countries, territories and areas participate in GLASS.
The fifth GLASS report, produced in collaboration with Member States, summarizes 2020 data on AMR rates in common bacteria from countries, territories, and areas. The report brings new features, including analyses of population testing coverage or AMR trends. For the first time, the report presents 2020 data on AMC at the national level. A new interactive dashboard allow users to explore AMR and AMC global data, country profiles and download the data.
This report marks the end of the early implementation phase of GLASS. In addition to presenting data collected through the latest data call, this report provides a summary of five years of national AMR surveillance data contributed to GLASS from its initiation, presents AMR findings in the context of progress of country participation in GLASS and in global AMR surveillance coverage and laboratory quality assurance systems at (sub)national level.
Patterns of antimicrobial consumption are presented by country with a particular focus on antibacterials. The report also presents the antimicrobial consumption according to the WHO AWaRe antibiotic classification, for penicillins and cephalosporines. From a One Health perspective, the report presents antimicrobial consumption data in the human sector expressed in tons to allow a comparison with antimicrobial consumption from other sectors (not included in this report).
more
WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI...D-19 public health response, from surveillance and laboratory testing to maintaining essential health services in the most vulnerable and fragile contexts.
more
A step towards implementation of the Convention on the Rights of Persons with Disabilities (CRPD) related to personal mobility.
WHO technical advisory group on behavioural insights and sciences for health, meeting report, 15 October 2020
Working document from an informal consultation of experts. A Protocol for risk assessment at the field level. The purpose of document is to provide guidance on the methodology to be used for assessing, at field level, the yellow fever virus circulation in areas at risk, and is primarily intended fo...r public health specialists
more
Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia | University of New South Wales, Sydney, Australia 16–18 March 2015
This research report provides results from the study on living conditions
among people with disabilities in Malawi. Comparisons are made between
individuals with and without disabilities and also between households with and without a disabled family member. Results obtained in Malawi are also comp...ared those obtained in earlier studies carried out in Namibia and Zimbabwe. The Malawian study was undertaken in 2003.
more
Ежегодно табак убивает более 7 миллионов человек (1), то есть ежедневно в результате употребления табака или воздействия вторичного табачного дыма (ВТД) умирает бол...е 19 000 человек. Большинство таких случаев смерти происходят в странах с низким и средним уровнем доходов, население которых подвергается активному маркетингу табачной промышленности.
more
Cet outil peut être utilisé pour améliorer la qualité du programme ASC. Pour identifier et combler les lacunes dans la conception et la mise en œuvre du programme ASC, veuillez compléter les informations ci-dessous
Guide des pratiques essentielles
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...ing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
more